Last reviewed · How we verify

Fasenra — Competitive Intelligence Brief

Fasenra (BENRALIZUMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]. Area: Immunology.

marketed Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] Interleukin-5 receptor subunit alpha Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Fasenra (BENRALIZUMAB) — AstraZeneca. Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fasenra TARGET BENRALIZUMAB AstraZeneca marketed Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] Interleukin-5 receptor subunit alpha 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fasenra — Competitive Intelligence Brief. https://druglandscape.com/ci/benralizumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: